Invesco
DSGN icon

Invesco’s Design Therapeutics DSGN Stock Holding History

Invesco’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Sell
141,920
-163,837
-54% -$1.66M ﹤0.01% 2677
2025
Q4 		$2.87M Buy
305,757
+291,168
+1,996% +$2.28M ﹤0.01% 2468
2025
Q3 		$110K Buy
14,589
+225
+2% +$1.13K ﹤0.01% 3672
2025
Q2 		$48.4K Buy
14,364
+3,033
+27% +$11.3K ﹤0.01% 3726
2025
Q1 		$43.7K Sell
11,331
-252
-2% -$1.2K ﹤0.01% 3708
2024
Q4 		$71.5K Buy
+11,583
New +$67K ﹤0.01% 3662
2024
Q2 		– Sell
-10,474
Closed -$42.2K – 3903
2024
Q1 		$42.2K Sell
10,474
-463
-4% -$1.24K ﹤0.01% 3815
2023
Q4 		$29K Buy
+10,937
New +$25.1K ﹤0.01% 3787
2022
Q4 		– Sell
-10,058
Closed -$168K – 4029
2022
Q3 		$168K Sell
10,058
-79
-0.8% -$1.57K ﹤0.01% 3727
2022
Q2 		$142K Buy
+10,137
New +$137K ﹤0.01% 3817
2022
Q1 		– Sell
-9,622
Closed -$206K – 4027
2021
Q4 		$206K Buy
+9,622
New +$165K ﹤0.01% 3764

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco's DSGN Position: Q1 2026 in Review

Invesco reduced its Design Therapeutics (DSGN) stake by 54% in Q1 2026, selling an estimated $1.66M and leaving 141,920 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2677.

Invesco first reported a position in DSGN in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.87M in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Invesco held 141,920 shares of Design Therapeutics worth $1.51M as of Q1 2026.
  • Invesco sold 163,837 Design Therapeutics shares in Q1 2026, an estimated $1.66M.
  • Design Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2677 holding.
  • Invesco first reported a position in Design Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Invesco's Design Therapeutics position peaked at $2.87M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.